{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:22:52Z","timestamp":1774581772911,"version":"3.50.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Canine lymphoma is one of the most common and aggressive hematopoietic tumors in dogs. Despite recent advances in veterinary cancer treatments, the lack of specificity, side effects, and resistance to conventional chemotherapies has opened an urgent need to develop more targeted and safe therapeutics to address this unmet need in dogs. Thus, in the present study, we aimed to generate a new class of therapeutics based on a recombinant single-domain antibody (sdAb) immunotoxin derived from the PE38 <jats:italic>Pseudomonas aeruginosa<\/jats:italic> exotoxin A. For this purpose, we fused the PE38 toxin with the specific C5 sdAb antibody, previously developed by our group for canine B-cell lymphoma. This resulted in a stable and highly specific C5-PE38 immunotoxin against canine B-cell lymphoma. The C5-PE38 immunotoxin revealed a potent cytotoxic activity (EC50\u202f=\u202f9.50\u202f\u00b1\u202f0.04\u202f\u03bcg\/mL) against CLBL-1 canine B-cell lymphoma cells, while promoting inhibition of protein synthesis and, consequently, cell death. Importantly, <jats:italic>in vivo<\/jats:italic> results in a CLBL-1 xenograft mouse model demonstrated specific targeted tumor uptake and strong tumor growth inhibition in C5-PE38 treated mice compared with control vehicle-treated mice. The results obtained provide new data validating immunotoxins and recombinant sdAb-PE38 based scaffolds as a novel and promising anti-cancer therapy for the treatment of dog-related tumors, while contributing to comparative oncology.<\/jats:p>","DOI":"10.3389\/fvets.2025.1491934","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T19:18:36Z","timestamp":1743794316000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["A new treatment for canine B-cell lymphoma based on a recombinant single-domain antibody immunotoxin derived from Pseudomonas aeruginosa exotoxin A"],"prefix":"10.3389","volume":"12","author":[{"given":"Ana S.","family":"Andr\u00e9","sequence":"first","affiliation":[]},{"given":"Joana N. R.","family":"Dias","sequence":"additional","affiliation":[]},{"given":"Isa","family":"Moutinho","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Loureiro","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Leonardo","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Nogueira","sequence":"additional","affiliation":[]},{"given":"Rafaela P.","family":"Marimon","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Bule","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Malh\u00f3","sequence":"additional","affiliation":[]},{"given":"Lurdes","family":"Gano","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o D. G.","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Solange","family":"Gil","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Frederico","family":"Aires-da-Silva","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cvsm.2023.12.004","article-title":"Novel treatments for lymphoma","volume":"54","author":"Thamm","year":"2024","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"k3204","DOI":"10.1136\/bmj.k3204","article-title":"Non-Hodgkin lymphoma","volume":"362","author":"Bowzyk Al-Naeeb","year":"2018","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"738693","DOI":"10.3389\/fmed.2021.738693","article-title":"Trends analysis of non-Hodgkin lymphoma at the national, regional, and global level, 1990\u20132019: results from the global burden of disease study 2019","volume":"8","author":"Cai","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-animal-022114-110911","article-title":"Dogs as a model for Cancer","volume":"4","author":"Gardner","year":"2016","journal-title":"Annu Rev Anim Biosci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"621758","DOI":"10.3389\/fvets.2021.621758","article-title":"Immunotherapeutic strategies for canine lymphoma: changing the odds against non-Hodgkin lymphoma","volume":"8","author":"Dias","year":"2021","journal-title":"Front Vet Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/biom11111696","article-title":"Immunotoxins: from design to clinical application","volume":"11","author":"Kreitman","year":"2021","journal-title":"Biomol Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.sbspro.2014.01.977","article-title":"Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer","volume":"11","author":"Weidle","year":"2014","journal-title":"Cancer Genomics Proteomics"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40259-023-00580-y","article-title":"Targeting the inside of cells with biologicals: toxin routes in a therapeutic context","volume":"37","author":"Ruschig","year":"2023","journal-title":"BioDrugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/08830185.2017.1284211","article-title":"Immunotoxins in cancer therapy: review and update","volume":"36","author":"Akbari","year":"2017","journal-title":"Int Rev Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/14737140.5.1.33","article-title":"Denileukin diftitox: a concise clinical review","volume":"5","author":"Eklund","year":"2005","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1158\/1078-0432.CCR-19-2329","article-title":"FDA approval summary: Tagraxofusp-erzs for treatment of Blastic Plasmacytoid dendritic cell neoplasm","volume":"26","author":"Jen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab Pasudotox: First Global Approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/1078155219838041","article-title":"Moxetumomab pasudotox: a first-in-class treatment for hairy cell leukemia","volume":"25","author":"Fancher","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3389\/fimmu.2020.01261","article-title":"Immunogenicity of immunotoxins containing Pseudomonas exotoxin a: causes, consequences, and mitigation","volume":"11","author":"Mazor","year":"2020","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/biom10070979","article-title":"Mechanisms of resistance to immunotoxins containing Pseudomonas exotoxin a in Cancer therapy","volume":"10","author":"Dieffenbach","year":"2020","journal-title":"Biomol Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.xphs.2019.10.037","article-title":"Critical issues in the development of immunotoxins for anticancer therapy","volume":"109","author":"Kim","year":"2020","journal-title":"J Pharm Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3390\/toxins12100658","article-title":"Immunotoxin screening system: a rapid and direct approach to obtain functional antibodies with internalization capacities","volume":"12","author":"Hamamichi","year":"2020","journal-title":"Toxins"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1038\/s41598-022-06549-1","article-title":"Characterization of the canine CD20 as a therapeutic target for comparative passive immunotherapy","volume":"12","author":"Dias","year":"2022","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/pharmaceutics13101598","article-title":"Highly specific blood-brain barrier transmigrating single-domain antibodies selected by an in vivo phage display screening","volume":"13","author":"Aguiar","year":"2021","journal-title":"Pharmaceutics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1038\/s41598-023-31568-x","article-title":"Rabbit derived VL single-domains as promising scaffolds to generate antibody\u2013drug conjugates","volume":"13","author":"Andr\u00e9","year":"2023","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1097\/QAD.0000000000001108","article-title":"Development of synthetic light-chain antibodies as novel and potent HIV fusion inhibitors","volume":"30","author":"Cunha-Santos","year":"2016","journal-title":"AIDS"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1111\/febs.14192","article-title":"Characterization of plasma labile heme in hemolytic conditions","volume":"284","author":"Gouveia","year":"2017","journal-title":"FEBS J"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jmb.2004.04.062","article-title":"Camelized rabbit-derived VH single-domain Intrabodies against Vif strongly neutralize HIV-1 infectivity","volume":"340","author":"Silva","year":"2004","journal-title":"J Mol Biol"},{"key":"ref27","volume-title":"Engineered rabbit antibody variable domains and uses thereof","author":"Braz Goncalves","year":"2008"},{"key":"ref28","volume-title":"Anti-tumor necrosis factor-alpha agents and uses thereof","author":"Aires-Da-Silva","year":"2012"},{"key":"ref29","volume-title":"Highly specific rabbit single-domain antibodies for drug delivery in immunotherapy applications","author":"Silva","year":"2023"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2165\/00063030-200822050-00003","article-title":"Recombinant antibodies as therapeutic agents: pathways for modeling new Biodrugs","volume":"22","author":"Aires da Silva","year":"2008","journal-title":"BioDrugs"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e40078","DOI":"10.1371\/journal.pone.0040078","article-title":"Authentication of primordial characteristics of the CLBL-1 cell line prove the integrity of a canine B-cell lymphoma in a murine in vivo model","volume":"7","author":"R\u00fctgen","year":"2012","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.leukres.2010.01.021","article-title":"Establishment and characterization of a novel canine B-cell line derived from a spontaneously occurring diffuse large cell lymphoma","volume":"34","author":"R\u00fctgen","year":"2010","journal-title":"Leuk Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.abj8754","article-title":"Accurate prediction of protein structures and interactions using a three-track neural network","volume":"373","author":"Baek","year":"2021","journal-title":"Science"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera-a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"e0208147","DOI":"10.1371\/journal.pone.0208147","article-title":"Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies","volume":"13","author":"Dias","year":"2018","journal-title":"PLoS One"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"28586","DOI":"10.18632\/oncotarget.25580","article-title":"The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma","volume":"9","author":"Dias","year":"2018","journal-title":"Oncotarget"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.2147\/OTT.S134584","article-title":"Clinical targeting recombinant immunotoxins for cancer therapy","volume":"10","author":"Li","year":"2017","journal-title":"Ottagono"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1182\/bloodadvances.2019000507","article-title":"Moxetumomab pasudotox for hairy cell leukemia: preclinical development to FDA approval","volume":"3","author":"Lin","year":"2019","journal-title":"Blood Adv"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1634\/theoncologist.2019-0370","article-title":"Contextualizing the use of Moxetumomab Pasudotox in the treatment of relapsed or refractory hairy cell leukemia","volume":"25","author":"Kreitman","year":"2020","journal-title":"Oncologia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin Moxetumomab Pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/hep.30949","article-title":"Engineered anti-GPC3 immunotoxin, HN3-ABD-T20, produces regression in mouse liver Cancer xenografts through prolonged serum retention","volume":"71","author":"Fleming","year":"2020","journal-title":"Hepatology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"32450","DOI":"10.18632\/oncotarget.10592","article-title":"Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"E6623","DOI":"10.1073\/pnas.1706055114","article-title":"Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma","volume":"114","author":"Li","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbt.2012.09.002","article-title":"Development of VEGFR2-specific Nanobody Pseudomonas exotoxin a conjugated to provide efficient inhibition of tumor cell growth","volume":"30","author":"Behdani","year":"2013","journal-title":"New Biotechnol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"34070","DOI":"10.18632\/oncotarget.8710","article-title":"Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells","volume":"7","author":"Tang","year":"2016","journal-title":"Oncotarget"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2147\/IJN.S127575","article-title":"Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential","volume":"12","author":"Yu","year":"2017","journal-title":"IJN"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"22048","DOI":"10.18632\/oncotarget.15833","article-title":"HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis","volume":"8","author":"Sokolova","year":"2017","journal-title":"Oncotarget"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"27055","DOI":"10.1038\/srep27055","article-title":"Immuno-targeting the multifunctional CD38 using nanobody","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/cmi.2015.91","article-title":"Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo","volume":"14","author":"Mazor","year":"2017","journal-title":"Cell Mol Immunol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jbiotec.2017.05.017","article-title":"Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins","volume":"253","author":"Cantante","year":"2017","journal-title":"J Biotechnol"},{"key":"ref51","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.751.11.2","volume-title":"Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma","author":"Henry","year":"2005"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1211\/0022357001774345","article-title":"Influence of immunogenicity on the pharmacokinetics of BMS-191352, a Pseudomonas exotoxin Immunoconjugate, in rats and dogs","volume":"52","author":"Damle","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ijc.32719","article-title":"A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera","volume":"146","author":"Jack","year":"2020","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1491934\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T19:18:42Z","timestamp":1743794322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1491934\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":53,"alternative-id":["10.3389\/fvets.2025.1491934"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2025.1491934","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"article-number":"1491934"}}